Your browser doesn't support javascript.
loading
Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease.
Schulze, Lisa Lou; Becker, Emily; Dedden, Mark; Liu, Li-Juan; van Passen, Chiara; Mohamed-Abdou, Mariam; Müller, Tanja M; Wiendl, Maximilian; Ullrich, Karen A M; Atreya, Imke; Leppkes, Moritz; Ekici, Arif B; Kirchner, Philipp; Stürzl, Michael; Sexton, Dan; Palliser, Deborah; Atreya, Raja; Siegmund, Britta; Neurath, Markus F; Zundler, Sebastian.
Afiliação
  • Schulze LL; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
  • Becker E; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
  • Dedden M; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
  • Liu LJ; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
  • van Passen C; Department of Surgery, Division of Molecular and Experimental Surgery, University Hospital Erlangen and Friedrich-Alexander Universität Erlangen-Nürnberg, Germany.
  • Mohamed-Abdou M; Department of Surgery, Division of Molecular and Experimental Surgery, University Hospital Erlangen and Friedrich-Alexander Universität Erlangen-Nürnberg, Germany.
  • Müller TM; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
  • Wiendl M; Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Germany.
  • Ullrich KAM; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
  • Atreya I; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
  • Leppkes M; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
  • Ekici AB; Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Germany.
  • Kirchner P; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
  • Stürzl M; Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Germany.
  • Sexton D; Institute of Human Genetics, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
  • Palliser D; Institute of Human Genetics, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
  • Atreya R; Department of Surgery, Division of Molecular and Experimental Surgery, University Hospital Erlangen and Friedrich-Alexander Universität Erlangen-Nürnberg, Germany.
  • Siegmund B; Shire HGT, a Takeda company, Cambridge, MA, USA.
  • Neurath MF; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
  • Zundler S; Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Germany.
J Crohns Colitis ; 17(11): 1817-1832, 2023 Nov 24.
Article em En | MEDLINE | ID: mdl-37208197
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / Colite Ulcerativa Limite: Animals Idioma: En Revista: J Crohns Colitis Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / Colite Ulcerativa Limite: Animals Idioma: En Revista: J Crohns Colitis Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha